Tolazamide , ≥96%(T) , 1156-19-0
Synonym(s):
1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea
CAS NO.：1156-19-0
Empirical Formula: C14H21N3O3S
Molecular Weight: 311.4
MDL number: MFCD00083504
EINECS: 214-588-3
| Pack Size | Price | Stock | Quantity |
| 250MG | RMB399.20 | In Stock |
|
| 1G | RMB1039.20 | In Stock |
|
| 5g | RMB3199.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 162-164°C |
| Boiling point: | 300°C (rough estimate) |
| Density | 1.2228 (rough estimate) |
| refractive index | 1.6740 (estimate) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | Very slightly soluble in water; freely soluble in chloroform; soluble in acetone; slightly soluble in ethanol (96%). |
| form | Solid |
| pka | 3.6(at 25℃) |
| color | White to Off-White |
| Water Solubility | 65.4mg/L(30 ºC) |
Description and Uses
Tolazamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2; IC50 = 4.2 μM in HEK293 cells transfected with the human receptor). It has no effect on glucose uptake in L6 rat skeletal muscle cells when used at a concentration of 0.6 mg/mL but enhances glucose uptake two-fold when used in combination with insulin. In vivo, tolazamide (128 mg/kg) reduces glomerulosclerosis and albumin excretion in a rat model of insulin-dependent diabetes induced by streptozotocin . Formulations containing tolazamide have been used in the treatment of type 2 diabetes.
This drug is also a derivative of first generation of sulfonylurea, and it possesses stimulatory action on β-cells in pancreas, as well as the same range of action as all other drugs of the group of examined compounds. Tolazamide is used for non-insulin-dependent diabetes mellitus without expressed microvascular complications.
